On March 26, 2026, Cue Biopharma, Inc. announced the appointment of Lucinda Warren as the Interim President and Chief Executive Officer, effective March 27, 2026. This decision follows the resignation of Usman Azam from his roles as President, Chief Executive Officer, and Board member, effective the same day. Warren, who has been with the company since February 2026 as Chief Financial and Business Officer, brings over 30 years of experience in the pharmaceutical and biotechnology sectors. Her previous roles include significant positions at Johnson & Johnson and Janssen Biologics. In her new role, Warren will continue to oversee the financial and business operations of the company while leading it through this transitional period. The company has also entered into an amended executive employment agreement with Warren, which includes an annual base salary of $525,000 and potential bonuses based on performance. The Board of Directors has expressed confidence in Warren's ability to guide the company during this time. The leadership change is expected to have a small positive effect on the stock price as the company stabilizes under new management.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.